Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda and Antibiotics in Resectable Pancreatic Adenocarcinoma
NCT03891979Phase 4Withdrawn
- Sponsor
- NYU Langone Health
- Start
- Jun 2019
- Primary completion
- Jun 2020
- Countries
- 1
01
Overview
A Phase 4 trial of pembrolizumab in pancreatic adenocarcinoma (PDAC), sponsored by NYU Langone Health. Planned start Jun 2019; status: withdrawn.
02
Drugs
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03891979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03891979.